Multi criteria decision making to select the best method for the preparation of solid lipid nanoparticles of rasagiline mesylate using analytic hierarchy process

Journal of Advanced Pharmaceutical Technology and Research

Volumn 5, Issue 3, 2014, Pages 115-121

  Kunasekaran, Viveksarathi ^a   Krishnamoorthy, Kannan ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

Criteria; desirability; dynamic sensitivity analysis; hierarchy

Indexed keywords

RASAGILINE; SOLID LIPID NANOPARTICLE;

ANALYTIC HIERARCHY PROCESS; ARTICLE; DECISION MAKING; DOUBLE EMULSION; DRUG STABILITY; EVAPORATION; HIGH PRESSURE HOMOGENIZATION; MICROEMULSION; NANOFABRICATION; PARTICLE SIZE; PHARMACEUTICS; POLYDISPERSITY INDEX; PRIORITY JOURNAL; PROCESS DESIGN; SENSITIVITY AND SPECIFICITY; SOLVENT INJECTION; ZETA POTENTIAL;

EID: 84925634485     PISSN: 22314040     EISSN: 09762094     Source Type: Journal    
DOI: 10.4103/2231-4040.137410     Document Type: Article

References (29)

1. Ashok KG, Ahmad T, Vaidya S, Ahmed J. Microemulsion route to the synthesis of nanoparticles. Pure Appl Chem 2008;80:2451-77.
2. Sosnik A, Amiji M. Nanotechnology solutions for infectious diseases in developing nations. Preface. Adv Drug Deliv Rev 2010;62:375-7.
3. Bhushan B. Handbook of Nanotechnology. 1 st ed. Heidelberg, Germany: Springer; 2004.
4. Gupta RB, Kompella UB. Drug and the pharmaceutical science. Nanoparticle Technology for Drug Delivery. Vol. 159. New York: Taylor and Francis; 2006. p. 1.
5. Spuch C, Saida O, Navarro C. Advances in the treatment of neurodegenerative disorders employing nanoparticles. Recent Pat Drug Deliv Formul 2012;6:2-18.
6. Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinsons disease. Clin Ther 2007;29:1825-49.
7. Fernández M, Negro S, Slowing K, Fernández-Carballido A, Barcia E. An effective novel delivery strategy of rasagiline for Parkinsons disease. Int J Pharm 2011;419:271-80.
8. Torchilin VP. Nanoparticulates as Drug Carriers. USA: Imperial College Press; 2006.
9. Swarbrick J. Drug and the pharmaceutical science. In: Krishna R, editor. Dose Optimization in Drug Development. Vol. 161. New York: Tay and Fran; 2006. p. 197.
10. Kousalya P, Reddy MG, Supraja S, Prasad VS. Analytical hierarchy process approach - An application, of engineering education. Math Aeterna 2012;2:861-78.
11. Ishizaka A, Labib A. Selection of new production facilities with the group analytic hierarchy process ordering method. Exp Syst Appl 2011;38:7317-25.
12. Velmurugan R, Selvamuthukumar S, Manavalan R. Multi criteria decision making to select the suitable method for the preparation of nanoparticles using an analytical hierarchy process. Pharmazie 2011;66:836-42.
13. Yang IT, Wang WC, Yang TI. Automatic repair of inconsistent pairwise weighting matrices in analytic hierarchy process. Autom Constr 2012;22:290-7.
14. Velmurugan R, Selvamuthukumar S. The analytic network process for the pharmaceutical sector: Multi criteria decision making to select the suitable method for the preparation of nanoparticles. Daru 2012;20:59.
15. Moorthi C, Kathiresan K. Fabrication of dual drug loaded polymeric nanosuspension: Incorporating analytical hierarchy process and data envelopment analysis in the selection of a suitable method. Int J Pharm Pharm Sci 2013;5:499-504.
16. Yousefpour M, Rahimi A. Characterization and selection of optimal parameters to achieve the best tribological performance of the electrodeposited Cr nanocomposite coating. Mater Des 2014;54:382-9.
17. Perez-Vega S, Senior P, Salmeron-Ochoa I, Nieva-de la Hidalgac A, Sharratt PN. Analytical hierarchy processes (AHP) for the selection of solvents in early stages of pharmaceutical process development. Process Saf Environ Prot 2011;89:261-7.
18. Blasi P, Giovagnoli S, Schoubben A, Puglia C, Bonina F, Rossi C, et al. Lipid nanoparticles for brain targeting I. Formulation optimization. Int J Pharm 2011;419:287-95.
19. Silva AC, González-Mira E, García ML, Egea MA, Fonseca J, Silva R, et al. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): High pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces 2011;86:158-65.
20. Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution. US Patent No 1993;5250236.
21. Doijad RC, Manvi FV, Godhwani DM, Joseph R, Deshmukh NV. Formulation and targeting efficiency of Cisplatin engineered solid lipid nanoparticles. Indian J Pharm Sci 2008;70:203-7.
22. Mayur K, Padhi BK, Chougule M, Mishra A. Methotrexate loaded solid lipid nanoparticles for topical treatment of psoriasis: Formulation and clinical implication. Drug Deliv Tech 2002;5:1-13.
23. Hou J, Zhou SW. New research on development of solid lipid nanoparticle. J Med Col PLA 2007;22:385-90.
24. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 2001;47:165-96.
25. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257-72.
26. Cavalli R, Donalisio M, Civra A, Ferruti P, Ranucci E, Trotta F, et al. Enhanced antiviral activity of Acyclovir loaded into beta-cyclodextrin-poly (4-acryloylmorpholine) conjugate nanoparticles. J Control Release 2009;137:116-22.
27. Yadav N, khatak S, Sara UV. Solid lipid nanoparticles a review. Int J App Pharm 2013;5:8-18.
28. Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. Poly (n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimers disease. Brain Res 2008;1200:159-68.
29. Kashanian S, Azandaryani AH, Derakhshandeh K. New surface-modified solid lipid nanoparticles using N-glutaryl phosphatidylethanolamine as the outer shell. Int J Nanomedicine 2011;6:2393-401.